Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.

Tung TT, Oanh DT, Dung PT, Hue VT, Park SH, Han BW, Kim Y, Hong JT, Han SB, Nam NH.

Med Chem. 2013 Dec;9(8):1051-7.

PMID:
23521008
2.

Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.

Oanh DT, Hai HV, Park SH, Kim HJ, Han BW, Kim HS, Hong JT, Han SB, Hue VT, Nam NH.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7509-12. doi: 10.1016/j.bmcl.2011.07.124. Epub 2011 Aug 6.

PMID:
22036991
3.

5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.

Huong TT, Dung do TM, Oanh DT, Lan TT, Dung PT, Loi VD, Kim KR, Han BW, Yun J, Kang JS, Kim Y, Han SB, Nam NH.

Med Chem. 2015;11(3):296-304.

PMID:
25256241
4.

Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.

Nam NH, Huong TL, Dung do TM, Dung PT, Oanh DT, Quyen D, Thao le T, Park SH, Kim KR, Han BW, Yun J, Kang JS, Kim Y, Han SB.

Eur J Med Chem. 2013;70:477-86. doi: 10.1016/j.ejmech.2013.10.045. Epub 2013 Oct 23.

PMID:
24185378
5.

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H.

Bioorg Med Chem. 2012 Jun 15;20(12):3865-72. doi: 10.1016/j.bmc.2012.04.032. Epub 2012 Apr 21.

PMID:
22579621
6.

Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.

Lee HY, Wang LT, Li YH, Pan SL, Chen YL, Teng CM, Liou JP.

Org Biomol Chem. 2014 Nov 28;12(44):8966-76. doi: 10.1039/c4ob00542b.

PMID:
25277250
7.

Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.

Cai J, Wei H, Hong KH, Wu X, Cao M, Zong X, Li L, Sun C, Chen J, Ji M.

Eur J Med Chem. 2015;96:1-13. doi: 10.1016/j.ejmech.2015.04.002. Epub 2015 Apr 6.

PMID:
25874326
8.

New aryldithiolethione derivatives as potent histone deacetylase inhibitors.

Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, Sparatore A.

Bioorg Med Chem. 2010 Jun 15;18(12):4187-94. doi: 10.1016/j.bmc.2010.05.011. Epub 2010 May 7.

PMID:
20576572
9.

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.

Cincinelli R, Musso L, Giannini G, Zuco V, De Cesare M, Zunino F, Dallavalle S.

Eur J Med Chem. 2014 May 22;79:251-9. doi: 10.1016/j.ejmech.2014.04.021. Epub 2014 Apr 8.

PMID:
24742384
10.

Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.

Chetan B, Bunha M, Jagrat M, Sinha BN, Saiko P, Graser G, Szekeres T, Raman G, Rajendran P, Moorthy D, Basu A, Jayaprakash V.

Bioorg Med Chem Lett. 2010 Jul 1;20(13):3906-10. doi: 10.1016/j.bmcl.2010.05.020. Epub 2010 May 15.

PMID:
20605448
11.

Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.

Li X, Hou J, Li X, Jiang Y, Liu X, Mu W, Jin Y, Zhang Y, Xu W.

Eur J Med Chem. 2015 Jan 7;89:628-37. doi: 10.1016/j.ejmech.2014.10.077. Epub 2014 Oct 29.

PMID:
25462271
12.

Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.

Zhou M, Ning C, Liu R, He Y, Yu N.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3200-3. doi: 10.1016/j.bmcl.2013.04.004. Epub 2013 Apr 11.

PMID:
23639537
13.

Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.

Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N.

J Med Chem. 2005 Feb 24;48(4):1019-32.

PMID:
15715470
14.

Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.

Zhu Y, Chen X, Wu Z, Zheng Y, Chen Y, Tang W, Lu T.

Arch Pharm Res. 2012 Oct;35(10):1723-32. doi: 10.1007/s12272-012-1003-0. Epub 2012 Nov 9.

PMID:
23139122
15.

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118. Epub 2009 Oct 30.

PMID:
19906529
16.

The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

Zeglis BM, Pillarsetty N, Divilov V, Blasberg RA, Lewis JS.

Nucl Med Biol. 2011 Jul;38(5):683-96. doi: 10.1016/j.nucmedbio.2010.12.008. Epub 2011 Mar 3.

17.

Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.

Liao V, Liu T, Codd R.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6200-4. doi: 10.1016/j.bmcl.2012.08.006. Epub 2012 Aug 9.

PMID:
22932316
18.

The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.

Zhang X, Zhang J, Tong L, Luo Y, Su M, Zang Y, Li J, Lu W, Chen Y.

Bioorg Med Chem. 2013 Jun 1;21(11):3240-4. doi: 10.1016/j.bmc.2013.03.049. Epub 2013 Mar 31.

PMID:
23602523
19.

Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.

Cho M, Choi E, Kim JH, Kim H, Kim HM, Lee JI, Hwang KC, Kim HJ, Han G.

ChemMedChem. 2014 Mar;9(3):649-56. doi: 10.1002/cmdc.201300393. Epub 2013 Dec 2.

PMID:
24376239
20.

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Zhang Y, Feng J, Jia Y, Wang X, Zhang L, Liu C, Fang H, Xu W.

J Med Chem. 2011 Apr 28;54(8):2823-38. doi: 10.1021/jm101605z. Epub 2011 Apr 5.

PMID:
21476600
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk